Jeisys Medical Inc. (KOSDAQ: 287410)

Market Cap	957.88B
Revenue (ttm)	167.82B
Net Income (ttm)	27.97B
Shares Out	74.49M
EPS (ttm)	362.04
PE Ratio	35.52
Forward PE	21.52
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,482
Open	12,860
Previous Close	12,860
Day's Range	12,860 - 12,890
52-Week Range	7,390 - 14,500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About Jeisys Medical

Jeisys Medical Inc. designs, develops, and manufactures medical device for plastic surgeons, dermatologist, physicians, and healthcare professionals in South Korea and internationally. The company offers products for treatment areas, such as skin rejuvenation, lifting/tightening, pigmentation treatments, fat reduction, acne, tattoo removal, and scars and striae distensae under the ULTRAcel Q+ system, Cellec V system, LIPOcel, AcGen, TRI-BEAM Premium, Edge ONE, SmoothCool, and ULTRAcel brands. It provides its products through a network of distri...

• Industry: Unit Investment Trusts, Face-Amount Certificate Offices, and Closed-End Management Investment Offices
• Founded: 2001
• Employees: 231
• Stock Exchange: KOSDAQ
• Ticker Symbol: 287410

Financial Performance

In 2023, Jeisys Medical's revenue was 143.03 billion, an increase of 22.72% compared to the previous year's 116.55 billion. Earnings were 24.80 billion, a decrease of -8.59%.